Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2023-10-19 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
关于召开2023年第一次临时股东大会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2023 first extraordinary general meeting of shareholders (临时股东大会) for Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), eligibility, agenda items, registration procedures, and contact information. There is no financial data, earnings, or report content included. The document is an announcement about the meeting itself, not the meeting materials or results. It is not a full annual or interim report, nor a proxy statement or voting results announcement. Given the content and length (2514 characters), it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about the shareholder meeting.
2023-10-19 Chinese
第三届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 11th meeting of the 3rd Board of Directors of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and mentions that some proposals will be submitted to the shareholders' meeting. The content focuses on board meeting decisions and governance matters, such as approval of core employees, equity incentive plans, and scheduling a shareholders' meeting. There is no financial data, earnings information, or audit content. The document is not a full report but an official announcement of board resolutions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear board meeting resolution content.
2023-10-19 Chinese
2022年股权激励计划预留授予的激励对象名单
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the list of reserved incentive recipients under the 2022 equity incentive plan. It includes details about stock options granted to core employees and mentions the approval process involving the board and shareholders. The content focuses on equity incentive allocation and related personnel, which aligns with announcements about share-based compensation plans. It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting result. The document is an announcement of equity incentive plan details, which fits best under Share Issue/Capital Change (SHA) as it relates to stock options and equity incentives.
2023-10-19 Chinese
第三届监事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 12th meeting of the 3rd Supervisory Board of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details meeting attendance, agenda items, voting results, and references to related announcements on the stock exchange platform. The content focuses on internal governance matters such as employee recognition and stock incentive plans, with no financial statements or detailed financial data presented. The document is relatively short (1300 characters) and serves as a meeting resolution announcement rather than a full report or financial disclosure. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or management bodies.
2023-10-19 Chinese
投资者关系活动记录表
Earnings Release Classification · 95% confidence The document is titled as an "投资者关系活动记录表" (Investor Relations Activity Record) and specifically mentions a "2023年半年度报告业绩说明会" (2023 Half-Year Report Earnings Explanation Meeting). The content includes detailed Q&A about the company's half-year financial performance, operational updates, R&D progress, and strategic outlook. It is a transcript or record of an earnings presentation meeting rather than the actual half-year financial report itself. The document length is 6426 characters, which is sufficient to contain substantive content but the format and content indicate it is an earnings explanation session rather than a full interim report. The document is not a full Interim/Quarterly Report (IR) because it does not contain actual financial statements or detailed financial data tables but rather a narrative Q&A session. It is also not a Call Transcript (CT) of a conference call but a record of an earnings presentation meeting. The best fitting category is Earnings Release (ER) as it is an initial announcement and explanation of the half-year financial results with key highlights and investor Q&A. Confidence is high given the detailed financial performance discussion and the nature of the document as an earnings explanation meeting record. H1 2023
2023-09-20 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" (Investor Relations Activity Record) and specifically mentions a "2023年半年度报告业绩说明会" (2023 Half-Year Report Earnings Explanation Meeting). The content includes detailed Q&A about the company's half-year financial performance, operational highlights, R&D progress, and strategic outlook. It is a transcript or record of an earnings presentation meeting rather than the actual half-year financial report itself. The document length is 6426 characters, which is sufficient for a detailed meeting record but not a full financial report. The document also references a link to the actual half-year report materials hosted elsewhere, indicating this is a meeting record or transcript. According to the filing definitions, a detailed transcript of an earnings call or earnings explanation meeting is classified as a Call Transcript (CT). Therefore, this document is best classified as a Call Transcript (CT).
2023-09-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.